234 related articles for article (PubMed ID: 12751915)
21. Longitudinal change in left ventricular hypertrophy in the elderly on antihypertensive therapy.
Ahmad A; Nawaz HM; Nevins L; Nawaz H
Conn Med; 2003 Feb; 67(2):67-73. PubMed ID: 12664833
[TBL] [Abstract][Full Text] [Related]
22. Regression of left ventricular hypertrophy--are there differences between antihypertensive agents?
Dahlöf B
Cardiology; 1992; 81(4-5):307-15. PubMed ID: 1363788
[TBL] [Abstract][Full Text] [Related]
23. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
24. Hypertension: are beta-blockers and diuretics appropriate first-line therapies?
Wilson MD; Weart CW
Ann Pharmacother; 1994 May; 28(5):617-25. PubMed ID: 7915151
[TBL] [Abstract][Full Text] [Related]
25. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
26. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
[TBL] [Abstract][Full Text] [Related]
28. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee.
Ramsey SD; Neil N; Sullivan SD; Perfetto E
J Am Board Fam Pract; 1999; 12(2):105-14. PubMed ID: 10220232
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
Schädlich PK; Brecht JG; Brunetti M; Pagano E; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2001; 19(5 Pt 1):497-512. PubMed ID: 11465309
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review.
Park C; Wang G; Durthaler JM; Fang J
Am J Prev Med; 2017 Dec; 53(6S2):S131-S142. PubMed ID: 29153114
[TBL] [Abstract][Full Text] [Related]
31. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
Hogan TJ; Elliott WJ; Seto AH; Bakris GL
Pharmacoeconomics; 2002; 20(1):37-47. PubMed ID: 11817991
[TBL] [Abstract][Full Text] [Related]
32. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects.
Yeh JM; Nohria A; Diller L
Ann Intern Med; 2014 May; 160(10):661-71. PubMed ID: 24842413
[TBL] [Abstract][Full Text] [Related]
33. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
[TBL] [Abstract][Full Text] [Related]
34. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
Cobiac LJ; Magnus A; Barendregt JJ; Carter R; Vos T
BMC Public Health; 2012 Jun; 12():398. PubMed ID: 22657090
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ
Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
[TBL] [Abstract][Full Text] [Related]
36. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
37. Goals of antihypertensive therapy.
McVeigh GE; Flack J; Grimm R
Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
39. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension.
Hilleman DE; Mohiuddin SM; Lucas BD; Stading JA; Stoysich AM; Ryschon K
Clin Ther; 1994; 16(1):88-102; discussion 87. PubMed ID: 7911403
[TBL] [Abstract][Full Text] [Related]
40. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
